Ehsan Sadri, MD
Ophthalmology · Newport Beach, CANPI 1114025780
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (46.3%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 22.3%. Reporting peaked in 2019 at $133,340 and has fallen 97.1% since, to $3,808 in 2025. Among ophthalmology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 630 payments — averaging $404.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson Surgical Vision, Inc.$57K
- Aerie Pharmaceuticals, Inc.$48K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$25K
- Kala Pharmaceuticals, Inc.$22K
- Sun Pharmaceutical Industries Inc.$19K
- Glaukos Corporation$16K
- plus $68K from 28 others
Across 153 payments — averaging $6941.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Oyster Point Pharma, Inc.$458K
- Glaukos Corporation$348K
- Alcon Research LLC$148K
- NEW World Medical,inc.$40K
- Sun Pharmaceutical Industries Inc.$37K
- Bausch & Lomb Americas Inc.$11K
- plus $19K from 2 others
What the payments were for
- Consulting fees$117,87046%
- Speaking & faculty fees$93,27537%
- Travel & lodging$19,0637%
- Food & beverage$20,2388%
- Gifts$190%
- Other$4,1682%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rhopressa$44,880
- Rocklatan$43,232
- Tecnis IOL$18,232
- Compact Intuitiv$16,500
- Healon Duet Pro$16,500
- Catalys Laser System$14,630
- BROMSITE$13,229
- LOTEMAX SM$12,187
- Healon Viscoelastics$12,000
- EYSUVIS$10,620
- Tecnis Symphony IOL$10,500
- Tecnis Symphony Toric IOL$10,500
- Flarex$10,307
- INVELTYS$9,679
- Tecnis Multifocal Family of 1-piece IOLS$9,600
- COMPACT INTUITIV Phacofragmentation System$9,600
- CATALYS SYSTEM$9,000
- Tecnis 1-piece IOL$7,200
- Tecnis 3-piece IOL$7,200
- XEN$6,218
How this compares
$254,634 in reported general payments places this provider in the 95th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 48 | $66,973 |
| CequaCyclosporine | 36 | $27,946 |
| XiidraLifitegrast | 12 | $22,344 |
| CombiganBrimonidine Tartrate/Timolol | 44 | $20,464 |
| LumiganBimatoprost | 33 | $18,107 |
| RhopressaNetarsudil Mesylate | 28 | $12,583 |
| EysuvisLoteprednol Etabonate | 25 | $12,239 |
| MoxifloxacinMoxifloxacin Hcl | 391 | $11,836 |
| Cyclosporine | 18 | $10,939 |
| Alphagan PBrimonidine Tartrate | 25 | $10,717 |
| VyzultaLatanoprostene Bunod | 18 | $10,123 |
| Prednisolone Acetate | 517 | $9,490 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 36 | $8,752 |
| Latanoprost | 481 | $5,301 |
| Ketorolac Tromethamine | 409 | $4,902 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Combigan, Lumigan, Alphagan P | $15,321 | $116,261150 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $6,392 | $32,46730 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $19,109 | $27,94636 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa | $48,043 | $12,58328 claims |
| Kala Pharmaceuticals, Inc.Eysuvis | $21,658 | $12,23925 claims |
| AlconSimbrinza | $6,902 | $8,75236 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $25,129 | $1,83813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in Newport Beach
- Sheri RowenNewport Beach$1M
- Daniel SchwartzSan Francisco$8M
- Michael BerlinWest Hollywood$5.7M
- Gilbert KlimanMenlo Park$1.5M
- Kuldev SinghStanford$1.5M
- Raymond DouglasBeverly Hills$1.3M
- John AffeldtLoma Linda$1.1M
- Srinivas SaddaPasadena$1M
- Savak TeymoorianLaguna Hills$955K
- Andrew MoshfeghiLos Angeles$895K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.